Cognition Therapeutics (CGTX) to Release Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is projected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Cognition Therapeutics to post earnings of ($0.16) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX opened at $0.44 on Wednesday. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The firm’s 50 day simple moving average is $0.60 and its two-hundred day simple moving average is $0.55. The stock has a market capitalization of $18.29 million, a P/E ratio of -0.45 and a beta of 1.03.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Chardan Capital reiterated a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research report on Wednesday, February 26th. Finally, HC Wainwright increased their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.